• Journal of the Korea Convergence Society
• /
• v.10 no.3
• /
• pp.23-30
• /
• 2019

The purpose of this study is to find out the structure of the substance that affects antidiabetic using the candidate drug information for diabetes treatment. A quantitative structure activity relationship model based on machine learning method was constructed and major molecular descriptors were determined for each experimental data variables from coefficient values using a partial least squares algorithm. The results of the analysis of the molecular access system fingerprint data reflecting the candidate drug structure information were higher than those of the in vitro data analysis in terms of goodness-of-fit, and the major molecular expression factors affecting the antidiabetic effect were also variously derived. If the proposed method is applied to the new drug development environment, it is possible to reduce the cost for conducting candidate screening experiment and to shorten the search time for new drug development.

• Journal of Obesity & Metabolic Syndrome
• /
• v.27 no.4
• /
• pp.238-247
• /
• 2018

Background: We aimed to estimate the proportion of patients with diabetes who achieved target glycemic control, to estimate diabetes-related costs attributable to poor control, and to identify factors associated with them in the United Arab Emirates. Methods: This retrospective cohort study used administrative claims data handled by Abu Dhabi Health Authority (January 2010 to June 2012) to determine glycemic control and diabetes-related treatment costs. A total of 4,058 patients were matched using propensity scores to eliminate selection bias between patients with glycosylated hemoglobin (HbA1c) <7% and HbA1c ${\geq}7%$. Diabetes-related costs attributable to poor control were estimated using a recycled prediction method. Factors associated with glycemic control were investigated using logistic regression and factors associated with these costs were identified using a generalized linear model. Results: During the 1-year follow-up period, 46.6% of the patients achieved HbA1c <7%. Older age, female sex, better insurance coverage, non-use of insulin in the index diagnosis month, and non-use of antidiabetic medications during the follow-up period were significantly associated with improved glycemic control. The mean diabetes-related annual costs were $2,282 and $2,667 for patients with and without glycemic control, respectively, and the cost attributable to poor glycemic control was $172 (95% confidence interval [CI], $164-180). The diabetes-related costs were lower with mean HbA1c levels <7% (cost ratio, 0.94; 95% CI, 0.88-0.99). The costs were significantly higher in patients aged ${\geq}65$ years than those aged ${\leq}44$ years (cost ratio, 1.45; 95% CI, 1.25-1.70). Conclusion: More than 50% of patients with diabetes had poorly controlled HbA1c. Poor glycemic control may increase diabetes-related costs.